「」肺癌患者治疗攻略: 以“基因”为指引, 掌握靶向药物治愈攻略!( 三 )


. Lancet Oncology:S1470204517307295.
[4
. Niederst M JHu HMulvey H Eet al. The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies[J
. Clinical Cancer Research 2015:1078-0432.CCR-15-0560.
[5
. Thress K SPaweletz C PFelip Eet al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M[J
. Nature Medicine 2015 21(6):560-562.
[6
. LINARDOUH. Assessment of somatic K-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents : a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer[J
. Lancet Oncology 2008 9.
[7
. Engelman J. A Zejnullahu K Mitsudomi T等. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling[J
. Science 316(5827):1039-1043.
[8
. Chabon J J Simmons A D Lovejoy A F et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients[J
2016 7: 11815.
[9
. Lecia V Sequist Ji-Youn Han Myung-Ju Ahn et al.Osimertinib plus savolitinib in patients with EGFR mutation-positive MET-amplified non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre open-label phase 1b study. The Lancet. 2020
[10
. Takezawa K Pirazzoli V Arcila M E et al. HER2 amplification: A potential mechanism of acquired resistance to egfr inhibition in EGFR -mutant lung cancers that lack the second-site EGFR T790M mutation[J
. 2012 2(10):922.
【「」肺癌患者治疗攻略: 以“基因”为指引, 掌握靶向药物治愈攻略!】封面图来源:摄图网


推荐阅读